PD-L1/PD-1 Axis in Multiple Myeloma Microenvironment and a Possible Link with CD38-Mediated Immune-Suppression

PD-1 Blockade Reinvigorates Bone Marrow CD8+ T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors

(2020) Minsuk Kwon et al.   CLINICAL CANCER RESEARCH

Daratumumab prevents programmed death ligand‐1 expression on antigen‐presenting cells in de novo multiple myeloma

(2020) Nicolas Stocker et al.   Cancer Medicine

PD-L1 expression in bone marrow plasma cells as a biomarker to predict multiple myeloma prognosis: developing a nomogram-based prognostic model

(2020) Byung-Hyun Lee et al.   Scientific Reports

Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer

(2020) Noffar Bar et al.   JCI Insight

The Circular Life of Human CD38: From Basic Science to Clinics and Back

(2020) Alberto L. Horenstein et al.   MOLECULES

Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells

(2020) Chen Zhu et al.   Frontiers in Immunology

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma

(2020) Harry Ho Man Ng et al.   Journal for ImmunoTherapy of Cancer

Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies

(2020) Christie P. M. Verkleij et al.   Cancers

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

(2019) Robert M. Samstein et al.   NATURE GENETICS

Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma

(2019) Hareth Nahi et al.   PLoS One

Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma

(2019) Ryo Nakagawa et al.   ANNALS OF HEMATOLOGY

PD-L1, LAG3, and HLA-DR are increasingly expressed during smoldering myeloma progression

(2019) Alberto Mussetti et al.   ANNALS OF HEMATOLOGY

Cancer stemness, intratumoral heterogeneity, and immune response across cancers

(2019) Alex Miranda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

(2019) Maria-Victoria Mateos et al.   Lancet Haematology

PD-1 signaling affects cristae morphology and leads to mitochondrial dysfunction in human CD8+ T lymphocytes

(2019) Jesús Ogando et al.   Journal for ImmunoTherapy of Cancer

Ruxolitinib (RUX) reverses checkpoint inhibition by downregulating PD-L1 expression in both multiple myeloma (MM) tumor and stromal cells

(2019) Haiming Chen et al.   Clinical Lymphoma Myeloma & Leukemia

Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab

(2019) Thomas G. Martin et al.   Cells

Bone marrow-derived mesenchymal stem cells promote cell proliferation of multiple myeloma through inhibiting T cell immune responses via PD-1/PD-L1 pathway

(2018) Dandan Chen et al.   CELL CYCLE

Regulation and Function of the PD-L1 Checkpoint

(2018) Chong Sun et al.   IMMUNITY

CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade

(2018) Limo Chen et al.   Cancer Discovery

Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD+

(2018) F. Morandi et al.   OncoImmunology

Pomalidomide Inhibits PD-L1 Induction to Promote Antitumor Immunity

(2018) Yuki Fujiwara et al.   CANCER RESEARCH

PD-1/PD-L1 inhibitors in haematological malignancies: update 2017

(2017) Tomas Jelinek et al.   IMMUNOLOGY

The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint

(2017) Qingshui Wang et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma

(2017) A Ray et al.   LEUKEMIA

Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy

(2017) K R Kelly et al.   LEUKEMIA

Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation

(2017) Federica Costa et al.   Oncotarget

Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells

(2017) Rachel M. Gibbons Johnson et al.   Frontiers in Immunology

Identifying Regulatory Posttranslational Modifications of PD-L1: A Focus on Monoubiquitinaton

(2017) Henrick Horita et al.   NEOPLASIA

Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication

(2016) G. An et al.   BLOOD

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

(2016) J. Krejcik et al.   BLOOD

Deubiquitination and Stabilization of PD-L1 by CSN5

(2016) Seung-Oe Lim et al.   CANCER CELL

Immunosuppressive activities of adenosine in cancer

(2016) Bertrand Allard et al.   CURRENT OPINION IN PHARMACOLOGY

T cells in multiple myeloma display features of exhaustion and senescence at the tumor site

(2016) Claudia Zelle-Rieser et al.   Journal of Hematology & Oncology

Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade

(2016) H Suen et al.   LEUKEMIA

PD-1/PD-L1 expression in extra-medullary lesions of multiple myeloma

(2016) Anna Crescenzi et al.   LEUKEMIA RESEARCH

Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates With Progression of Human Myeloma

(2016) Alberto L Horenstein et al.   MOLECULAR MEDICINE

Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway

(2016) Vassiliki A. Boussiotis   NEW ENGLAND JOURNAL OF MEDICINE

Potential biomarker for checkpoint blockade immunotherapy and treatment strategy

(2016) Zhong-Yi Dong et al.   TUMOR BIOLOGY

Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma

(2016) Shang-Yi Huang et al.   Oncotarget

Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1

(2016) M. Ishibashi et al.   Cancer Immunology Research

Targeting CD73 in the tumor microenvironment with MEDI9447

(2016) Carl M. Hay et al.   OncoImmunology

Regulation of PD-L1: a novel role of pro-survival signalling in cancer

(2015) J. Chen et al.   ANNALS OF ONCOLOGY

Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy

(2015) M. V. Dhodapkar et al.   BLOOD

Biomarkers in Cancer Immunotherapy

(2015) Ton N. Schumacher et al.   CANCER CELL

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression

(2015) Chih-Hao Chang et al.   CELL

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma

(2015) G. Gorgun et al.   CLINICAL CANCER RESEARCH

PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma

(2015) B Paiva et al.   LEUKEMIA

Targeting PD1–PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells

(2015) A Ray et al.   LEUKEMIA

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation

(2015) Nikolaos Patsoukis et al.   Nature Communications

Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients

(2015) S Yousef et al.   Blood Cancer Journal

A non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferation

(2015) Fabio Morandi et al.   Oncotarget

Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma

(2015) Liang Wang et al.   Oncotarget

Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma

(2015) Barbara Castella et al.   OncoImmunology

PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy

(2015) Anne-Marit Sponaas et al.   PLoS One

Mechanisms of Hypoxia-Mediated Immune Escape in Cancer

(2014) I. B. Barsoum et al.   CANCER RESEARCH

IFN-  Arms Human Dendritic Cells to Perform Multiple Effector Functions

(2014) L. Frasca et al.   JOURNAL OF IMMUNOLOGY

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

(2014) Matthew M. Gubin et al.   NATURE

Immunological Dysregulation in Multiple Myeloma Microenvironment

(2014) Alessandra Romano et al.   Biomed Research International

Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs

(2013) B. Allard et al.   CLINICAL CANCER RESEARCH

Hypoxia-induced and A2A adenosine receptor-independent T-cell suppression is short lived and easily reversible

(2013) Akio Ohta et al.   INTERNATIONAL IMMUNOLOGY

Programmed Death Receptor-1/Programmed Death Receptor Ligand-1 Blockade after Transient Lymphodepletion To Treat Myeloma

(2013) T. J. Kearl et al.   JOURNAL OF IMMUNOLOGY

Autocrine Adenosine Signaling Promotes Regulatory T Cell-Mediated Renal Protection

(2012) G. R. Kinsey et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma

(2012) H Tamura et al.   LEUKEMIA

Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting

(2012) Hirokazu Matsushita et al.   NATURE

Extracellular purine metabolism and signaling of CD73-derived adenosine in murine Treg and Teff cells

(2011) Michael Romio et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

Immunosuppressive Effects of Multiple Myeloma Are Overcome by PD-L1 Blockade

(2011) William H.D. Hallett et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Cutting Edge: Distinct Glycolytic and Lipid Oxidative Metabolic Programs Are Essential for Effector and Regulatory CD4+ T Cell Subsets

(2011) R. D. Michalek et al.   JOURNAL OF IMMUNOLOGY

PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine

(2011) Jacalyn Rosenblatt et al.   JOURNAL OF IMMUNOTHERAPY

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

(2010) D. M. Benson et al.   BLOOD

A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma

(2010) K. Noonan et al.   BLOOD

Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target

(2009) Dharminder Chauhan et al.   CANCER CELL

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells

(2008) T. Azuma et al.   BLOOD

Adenosine receptors in regulation of dendritic cell differentiation and function

(2008) S. V. Novitskiy et al.   BLOOD

Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology

(2008) Fabio Malavasi et al.   PHYSIOLOGICAL REVIEWS

The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors

(2008) D. Y.-w. Lin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA